Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 2;13(3):465.
doi: 10.3390/biom13030465.

CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy

Xi-Wen Zhang  1 , Yi-Shi Wu  1 , Tian-Min Xu  1 , Man-Hua Cui  1
Affiliations
Review

CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy

Xi-Wen Zhang et al. Biomolecules. .

Abstract

Ovarian cancer (OC) is among the most common gynecologic malignancies with a poor prognosis and a high mortality rate. Most patients are diagnosed at an advanced stage (stage III or IV), with 5-year survival rates ranging from 25% to 47% worldwide. Surgical resection and first-line chemotherapy are the main treatment modalities for OC. However, patients usually relapse within a few years of initial treatment due to resistance to chemotherapy. Cell-based therapies, particularly adoptive T-cell therapy and chimeric antigen receptor T (CAR-T) cell therapy, represent an alternative immunotherapy approach with great potential for hematologic malignancies. However, the use of CAR-T-cell therapy for the treatment of OC is still associated with several difficulties. In this review, we comprehensively discuss recent innovations in CAR-T-cell engineering to improve clinical efficacy, as well as strategies to overcome the limitations of CAR-T-cell therapy in OC.

Keywords: CAR; CAR-T; immunotherapy; ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of allogeneic CAR-T-cell production.
Figure 2
Figure 2
Antigenic targets of OC cells and related functions of CAR-T cells targeting these tumor antigens.
Figure 3
Figure 3
The challenges for CAR-T-cell therapy for the treatment of OC.
Figure 4
Figure 4
Mechanisms of tumor immune escape.
Figure 5
Figure 5
Different types of CAR-T cells are designed to inhibit immune escape.
Figure 6
Figure 6
Schematic diagram of six methods to improve the therapeutic effect of CAR-T-cell therapy.
Figure 7
Figure 7
Ways to improve CAR-T-cell therapy.
Figure 8
Figure 8
Mechanism of chemotherapy to improve the effect of CAR-T therapy.
Figure 9
Figure 9
Mechanism diagram of radiotherapy to enhance the therapeutic effect of CAR-T-cell therapy.
See this image and copyright information in PMC

References

    1. Yan W., Hu H., Tang B. Advances of Chimeric Antigen Receptor T Cell Therapy in Ovarian Cancer. OncoTargets Ther. 2019;12:8015–8022. doi: 10.2147/OTT.S203550. - DOI - PMC - PubMed
    1. International Agency for Research on Cancer Survival, Incidence, and Mortality over Time. [(accessed on 23 December 2022)]. Available online: https://gco.iarc.fr/survival/survmark/
    1. Yan L., Liu B. Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors. OncoTargets Ther. 2018;12:193–204. doi: 10.2147/OTT.S190336. - DOI - PMC - PubMed
    1. Majzner R.G., Mackall C.L. Tumor Antigen Escape from CAR T-cell Therapy. Cancer Discov. 2018;8:1219–1226. doi: 10.1158/2159-8290.CD-18-0442. - DOI - PubMed
    1. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850–854. doi: 10.1126/science.1076514. - DOI - PMC - PubMed

Publication types

Substances